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Edited by Varda RotterAbstract Heat shock protein (Hsp) in tumor cells has been pro-
posed to enhance their resistance to chemotherapeutic agents. In
the present study, we investigated the inﬂuence of Hsp expression
on the irinotecan resistance of human colorectal cancer cells.
Among eight Hsp genes tested in this study, we conﬁrmed that
the expression of Hsp27 correlated with irinotecan resistance
in colorectal cancer cells. Speciﬁc inhibition of Hsp27 expression
using an antisense oliogodeoxynucleotide increased the irino-
tecan sensitivity. On the contrary, an overexpression of Hsp27
decreased the irinotecan sensitivity in colorectal cancer cells.
Elevated expression of Hsp27 decreased caspase-3 activity in
colorectal cancer cells. The expression level of Hsp27 determined
by immunohistochemical analysis correlated with the clinical re-
sponse to irinotecan in colorectal cancer patients. Hsp27 expres-
sion levels of irinotecan-non-responder (mean staining score,
6.28; proportion of high staining score, 64.2%) were signiﬁcantly
higher compared to those of irinotecan-responder (mean staining
score, 3.16; proportion of high staining score, 33.3%) (P for t-
test = 0.045). These ﬁndings suggest that Hsp27 is involved in
the irinotecan resistance of colorectal cancer cells possibly by
reducing caspase-3 activity.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Irinotecan (CPT-11) is a topoisomerase I (Top1) inhibitor
that has eﬃcacy in the treatment of certain neoplasm including
colorectal cancer [1]. Irinotecan treatment results collisions be-
tween Top1 cleavage complexes and DNA replication forks
that produce irreversible double-strand breaks, ultimately
leading to irreversible DNA damage and to a series of events
that result in apoptosis [2,3]. Despite an initial response to
therapy, most patients treated with irinotecan become resistantAbbreviations: Hsp, heat shock protein; ODN, oliogodeoxynucleotide;
TUNEL, TdT-mediated dUTP nick end labeling
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on preclinical studies, it is likely that clinical resistance to this
drug is the result of (a) inadequate accumulation of drug in the
tumors, (b) resistance-conferring alterations in Top1-irino-
tecan interaction, or (c) alterations in cellular responses to
the Top1-irinotecan interaction [5].
Recent experimental evidence suggests that heat shock pro-
teins (Hsps) like Hsp27, Hsp70, and Hsp90 are overexpressed
in several tumor cells [6,7]. For example, Hsp27, a small Hsp,
is abundantly expressed in colon carcinoma cells [8] and many
other cancer cells [9], Hsp70 is highly expressed in human
breast tumors and is needed for their survival [10], and expres-
sion of Hsp90 was elevated in prostate carcinoma [11]. Hsps
can inhibit apoptosis by interaction with apoptotic molecules
[12–15] and high expression of Hsps has been shown to protect
tumor cells from apoptosis by several commonly used antican-
cer drugs [12,16–20].
Apoptosis induction is an important mechanism in the irino-
tecan-induced killing of tumors [2,3] and, thus, inhibition of
apoptosis by Hsps can induce a resistance to irinotecan. How-
ever, the role of Hsps in the irinotecan resistance of cancer cells
is poorly understood. In the present study, we have examined
the eﬀect of an overexpression of Hsps on the irinotecan resis-
tance of human colorectal cancer cells. Our study indicates
that Hsp27 is overexpressed in irinotecan-resistant colorectal
cancer cells. Hsp27 inhibition using Hsp27 antisense oli-
ogodeoxynucleotide (ODN) increased the irinotecan sensitivity
of colorectal cancer cells and, on the contrary, an overexpres-
sion of Hsp27 increased the irinotecan resistance of the colo-
rectal cancer cells. Immunohistochemical analysis on resected
specimens before irinotecan treatment showed a clinical rela-
tionship between Hsp27 expression levels and irinotecan resis-
tance in colorectal cancer patients. Our results suggested that
Hsp27 expression is associated with the irinotecan resistance
of colorectal cancer cells.2. Materials and methods
2.1. Cell culture and cell line selection
Four human colorectal cancer cell lines, Colo320HSR, KM20,
KM12C, and KM1214 were purchased from Korean Cell Line Bank
(KCLB) (Seoul, Korea) and were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(GibcoBRL), 100 U of penicillin, and 100 lg of streptomycin/ml. They
were cultured at 37 C in a humidiﬁed chamber containing 5% CO2.blished by Elsevier B.V. All rights reserved.
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prior to irinotecan treatment. Relative irinotecan cytotoxicity of the
four cell lines was evaluated using an MTT colorimetric assay. Brieﬂy,
cells were plated in triplicate at 1.2 · 104 cells/well in 96-well culture
plates in DMEM. On the following day, the cells were treated with iri-
notecan at concentrations ranging from 0 to 400 lM. On the consecu-
tive days, the cells were incubated with MTT dye (1 mg/ml) at 37 C
for 4 h and lysed in a buﬀer containing 20% (w/v) SDS, 50% (v/v)
N,N-dimethylformamide (pH 4.5). Absorbance at 600 nm (OD600)
was determined for each well using an ELX 808 automated microplate
reader (Bioteck Instrument).
2.2. TdT-mediated dUTP nick end labeling (TUNEL) staining
TUNEL staining was conducted using an in situ cell death detection
kit, TMR Red, according to the protocol supplied by the manufacturer
(Roche Molecular Biochemicals). Brieﬂy, cells were plated in 25 cm2
ﬂasks at 2 · 105 cells/ml DMEM. On the following day, the cells were
treated with 50 lM irinotecan, harvested and were ﬁxed with 2% para-
formaldehyde solution and permeabilized with 0.1% Triton X-100 in
0.1% sodium citrate. After washing twice with PBS, cells were incu-
bated in a TUNEL reaction mixture containing terminal deoxynucleo-
tidyl transferase and tetramethyl-rhodamine-dUTP. Cells were
analyzed for ﬂuorescence intensity using a FACS ﬂow cytometer (Bec-
ton Dickinson, Inc.) and a FluoView 500 confocal microscope
(Olymphus).
The eﬀects of the caspase-3 inhibitor, Ac-DEVD-CHO (Calbiochem,
USA), on irinotecan-induced apoptosis were determined by adding
3 lM or 10 lM Ac-DEVD-CHO to cultured cells 1 h prior to treat-
ment with 50 lM irinotecan.
2.3. Semi-quantitative RT-PCR and real-time PCR
Five micrograms of DNase I-treated total RNA was reverse
transcribed using oligo-dT and Superscript II reverse transcriptase
(Invitrogen), according to the manufacturer’s instructions. Semi-
quantitative RT-PCR was performed using Taq polymerase (Qiagen)
and appropriate primers. Quantitative PCR was performed by moni-
toring in real-time the increase in ﬂuorescence of the SYBR Green
dye (Molecular Probes, Eugene, OR) on a DNA Engine Opticon Con-
tinuous Fluorescence Detection System (MJ Research Inc.) according
to the manufacturer’s instructions. Speciﬁcities of each primer pair
were conﬁrmed by melting curve analysis and agarose-gel electropho-
resis.
2.4. PCR primers
Primers were designed using the Primer3 software: http://www-gen-
ome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi. PCR primer pairs
were as follows. Hsp27: GTCCCTGGATGTCAACCACT, CTTTAC-
TTGGCGGCAGTCTC; Hsp40: ATGGTACCTCTTTCAGCTACA-
CATT, GAGATTTTCATCTTCTTGGTACAGC; Hsp60: TCTTAT-
GA-TAGAGTGTTCAGCCAGA, TGTAAAGATCCATCCCTTTT-
CATAG; Hsp70: AGGTAAGGCTAACAAGATCACCAAT, CTTC-
TGATGCTCATACTCCTCCTT; GRP78: TTCTTCAATGGCAAG-
GAACC, TTTGTCAGGGGTCTTTCACC; Hsp90a: GGCAGAG-
GCTGATAAGAACG, AGTCATCCCTCAGCCAGAGA; Hsp-
90b: TCCATCTATTACATCACTGGTGAGA, GATTGTCAC CT-
TCTCAACCTTCTTA; GRP94: TCCATGATATGATGCCTAAAT-
ACCT, TAATGTCAGTTGGATGATGAGAAGA.
2.5. Plasmid construction and transfection
KM12C cells that overexpressed human Hsp27 were generated using
the pcDNA3.1/Myc-His A vector (Invitrogen). Full-length human
cDNA of Hsp27 was cloned by RT-PCR from the RNA of Colo320
cell lines using a forward primer GAATTCATGACCGAGCGCCG-
CGTC and a reverse primer CTCGAGCTTGGCGGCAGTCTCATC
and subcloned into the pcDNA3.1/Myc-His A vector. KM12C cells
were transfected with pcDNA3.1-Hsp27 construct using Lipofect-
amine (GibcoBRL). KM12C/Hsp27 cells stably transfected with
Hsp27 were selected by adding neomycin (200 lg of neomycin/ml;
Invitrogen) 3 days after transfection and stably transfected cells were
tested for an overexpression of Hsp27 by RT-PCR. KM12C/pcDNA
cells was generated by transfection with pcDNA3.1/Myc-His vector
and used as controls. A region of Hsp27 (5 0-GTCAGCCAGCAT-
GACCGAGC-3 0) was chosen as the target for Hsp27 antisense
ODN. An Hsp27 scrambled ODN with the same nucleotide composi-tion as Hsp27 antisense ODN but which lacked signiﬁcant sequence
homology to the Hsp27 was also designed as a negative control. The
phosphorothioate/phosphodiester chimeric ODNs were purchased
from Integrated DNA Technologies (Coralville, IA, USA). 5 · 105
cells were plated on culture ﬂask (25 cm2) on day 0 and transfection
was performed on day 1 using oligofectamine (GIBCO-BRL) accord-
ing to the manufacturer’s protocol in the presence of 200 nM of
ODNs. Two days after the transfection, cells were treated with
50 lM irinotecan for 24 h.
2.6. Construction of DRG2 luciferase reporter constructs and luciferase
assay
PCR was performed to amplify promoter region (from 724 to 35;
translation start site, +1) of Hsp27 which is required for Hsp27 pro-
moter activity [21]. Primers for PCR were designed from the genomic
sequence adjacent to the human hsp27 exon 1 in a GenBank database
of human chromosome 7. Hsp27-Pm-Up, 5 0-GGTACCACAGG-
CATGCACCAC-3 0; Hsp27-Pm-Down, 5 0-CTCGAGAAGTGCGG-
GGCGCTG-30. The PCR product (701 bp) ampliﬁed from human
genomic DNA was ligated into the Kpn1/Xho1 site of the promoterless
luciferase-reporter vector pGL3-basic (Promega).
Cells were grown to a density of about 40% conﬂuency and trans-
fected with 200 ng of hsp27 promoter luciferase-reporter construct,
pGL3/Hsp27 promoter, using 3 ll/g DNA of Lipofectamin in a vol-
ume of 50 ll Opti-MEM (Gibco BRL). Twenty four hours after
transfection, cells were treated with 50 lM irinotecan for 24 h. Trans-
fection eﬃciency was normalized by cotransfecting the plasmid
pCMV-b-gal (Clontech, Palo Alto, CA, USA) at 20 ng/ml. Both the
luciferase assay (Luciferase Assay System, Promega) and the b-galac-
tosidase assay were carried out according to the manufacturer’s
instructions as reported [22]. In both cases, the chemiluminescent sig-
nal was determined in a luminometer (VICTOR2 Multilabel Reader,
Wallac).
2.7. Caspase-3 activity assay
Cells were lysed in lysis buﬀer (10 mMHEPES, pH 7.4, 10% sucrose,
2 mM EDTA, 0.1% CHAPS, 10 mM dithiothreitol, 1 mM phenyl-
methylsulfonyl ﬂuoride, and 20 lg/ml each of pepstatin A, leupeptin,
and aprotinin) for 15 min on ice. After centrifugation at 15000 · g
for 15 min at 4 C, supernatants containing 50 lg of protein were incu-
bated with 50 lM Ac-DEVD-AFC for 1 h. Caspase-3 activity was
determined by ﬂuorometric detection of the hydrolyzed product using
a microplate spectroﬂuorometer (VICTOR2 Multilabel Reader, Wal-
lac).
2.8. Immunoblot analysis
Cells were washed twice with cold-phosphate-buﬀered saline and 30–
50 lg of protein was resolved by SDS–PAGE, transferred onto Hy-
bond-P membranes (Amersham Biosciences, Inc.), and probed with
appropriate dilutions of the following primary antibodies: anti-
Hsp27 (F-4) (Santa Cruz Biotechnology); anti-caspase 3 (CPP32) (Sig-
ma). Immunoreactivity was detected using the ECL detection system
(Amersham Biosciences, Inc.). The ﬁlms were exposed at multiple time
points to ensure that the images were not saturated.
2.9. Patients and samples
The study group was composed of 20 patients with colorectal cancer
who underwent surgical treatment at our Hospital and had a follow-up
therapeutic treatment with irinotecan. Irinotecan was administrated
i.v. at 180 mg/m2 for 90 min and 5-FU 400 mg/m2 over 2 days and leu-
kovorin, 200 mg/m2, six times, at 2-week intervals until there was evi-
dence of disease progression (FOLFIRI regimen). Response to
irinotecan was evaluated every cycle (i.e., every 2 or 3 months), based
on (a) computed tomography performed every cycle and (b) serum
CEA level (i.e., every 4 weeks). To be classiﬁed as ‘‘responder’’,
patients had to be rated improved for one or two measures without
being assessed as aggravated for the other factor. Otherwise, patients
were classiﬁed as ‘‘non-responder’’. The surgical colorectal samples
were ﬁxed in 10% buﬀered formalin, embedded in paraﬃn wax using
standard procedures, and were later used for immunohistochemical
analyses.
The Local Ethical Committee of our hospital provided institutional
review board approval for this study. Because this study was per-
formed on archival material, we did not obtain informed consent.
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The paraﬃn blocks of the most representative tumor tissues fulﬁlling
the histological criteria were cut on to poly-L-lysin-coated slides. The
sections were deparaﬃnized and rehydrated, and endogenous peroxi-
dase activity was blocked using a 0.3% hydrogen peroxide solution
at room temperature for 10 min. For epitope retrieval before immuno-
staining, slides were preheated with 0.01 M citrate buﬀer, pH 6.0 (three
times for 10 min at 700 W) and allowed to cool to room temperature
for 20 min. The sections were then incubated with primary anti-human
Hsp27 monoclonal antibody (F-4) (Santa Cruz Biotechnology) at 4 C
overnight. On the next day, primary antibodies were detected by using
a commercial kit (DAKO LSAB kit, Carpinteria, CA). Brieﬂy, a bio-
tinylated linking antibody and a streptavidin peroxidase complex were
added consecutively for 10 min at room temperature. After washing
twice in PBS, peroxidase activity was visualized with 3-amino-9-ethyl
carbazole (Sigma). The sections were counterstained with Mayer’s
hematoxylin. The negative control was stained by omitting the primary
antibody incubation. All the tumor tissue in the section was selected
for immunohistochemical evaluation. The Hsp27 expression was
scored semiquantitatively based on the staining intensity and propor-
tion of staining. Staining intensity was scored as 0–10%, 0; 11–50%,
1; 51–75%, 2; and 76–100%, 3 and proportion of staining was scored
as 0–25%, 1; 26–50%, 2; 51–75%, 3; 76–100%, 4. Staining scores were
obtained by a multiplication of staining intensity by proportion of
staining. Two pathologists, who did not have any prior clinical or
pathological information, scored the expression at 100· magniﬁcation
in light microscopy. All the available areas in the section were evalu-
ated.Time (hrs)
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Fig. 1. Selection of irinotecan-sensitive (KM12C) and irinotecan-
resistant (Colo320) cell lines. (A) Irinotecan cytotoxicity assay for the
four colorectal cancer cell lines. Cell lines were plated at equal density
on day zero, and treated with increasing concentrations of irinotecan
on day 1. Viability for all cell lines was determined by MTT on day 2.
(B) Irinotecan induced apoptosis of cells in a time-dependent manner.
KM12C and Colo320 cells were treated with 50 lM irinotecan for the
indicated times. Cells were then ﬁxed with 2% paraformaldehyde,
stained with TUNEL, and analyzed by FACS. The results are
presented as the means ± S.D. from three separate experiments.3. Results
3.1. Irinotecan cytotoxicity assay
To select cell lines with diﬀerent irinotecan sensitivity, we
determined the irinotecan sensitivity among four colorectal
cancer cell lines. There was variable irinotecan sensitivity
among those four cell lines. The IC50 for the most resistant cell
line, Colo320, was approximately 10 times higher than the IC50
for the most sensitive cell line, KM12C. The results of the cyto-
toxicity assay are shown in Fig. 1A. To examine the ability of
irinotecan to induce apoptosis in Colo320 and KM12C cells,
cultures were treated with 50 lM irinotecan, after which they
were stained with TUNEL and examined by FACS analysis.
As shown in Fig. 1B, irinotecan caused the apoptosis of
KM12C cells and irinotecan-induced apoptosis began to be de-
tected after 18 h of treatment of irinotecan and increased dra-
matically thereafter resulting in the death of greater than 43%
of the cell population by 24 h of treatment. However, the irino-
tecan treatment did not cause a signiﬁcant increase in apopto-
sis of Colo320 cells until 24 h of irinotecan treatment.3.2. Expressions of Hsps in Colo320 and KM12C cell lines
To determine whether or not the expression levels of Hsps
were related to irinotecan resistance, mRNA expression levels
of Hsp27, Hsp40, Hsp60, Hsp70, Hsp90a, Hsp90b, GRP78,
and GRP94 were evaluated by RT-PCR and real-time PCR
in irinotecan-treated Colo320 and KM12C cells. The expres-
sion levels of three Hsps, such as Hsp90a, Hsp90b and
GRP78, were signiﬁcantly higher than those of ﬁve other Hsps
such as Hsp27, Hsp40, Hsp60, Hsp70 and Grp94, both in the
irinotecan-treated Colo320 and KM12C cells (Fig. 2A and B).
However, the expression levels of the three Hsps in irinotecan-
treated Colo320 cells were similar to those in irinotecan-trea-
ted KM12C cells, suggesting that expression levels of the three
Hsps were not related to irinotecan resistance. On the con-
trary, among the ﬁve Hsps with low expression levels, theexpression level of Hsp27 showed signiﬁcant diﬀerence be-
tween the two cell lines and was about 35-fold higher in the iri-
notecan-treated Colo320 cells than in the irinotecan-treated
KM12C cells in real-time PCR analysis (Fig. 2A and B), sug-
gesting the possibility that the expression level of Hsp27 is re-
lated to the irinotecan resistance. Under normal conditions,
the expression level of Hsp27 showed about 7-fold diﬀerence
between Colo320 cells and KM12C cells. However, irinotecan
treatment caused a signiﬁcant diﬀerence in the expression level
of Hsp27 between the two cell lines (Fig. 2C). In irinotecan-
sensitive KM12C cells, irinotecan treatment caused a slight
decrease in Hsp27 expression level. However, in irinotecan-
resistant Colo320 cells, irinotecan treatment increased Hsp27
expression level by 3-fold (Fig. 2C).3.3. Hsp27 expression and irinotecan sensitivity in colorectal cell
lines
To determine whether or not Hsp27 expression is correlated
with irinotecan resistance, we analyzed the Hsp27 expression
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Fig. 2. Diﬀerential expression of Hsp27 between irinotecan-sensitive and irinotecan-resistant cells. (A) Expressions of 8 Hsp genes in KM12C and
Colo320 cells 24 h after irinotecan treatment were determined by semiquantitative RT-PCR analysis and the PCR products were analyzed by 1%
agarose gel electrophoresis and stained with ethidium bromide. (B) Quantitative, real-time RT-PCR analysis of 8 Hsp mRNAs expression in KM12C
and Colo320 cells 24 h after irinotecan treatment. (C) Expression levels of Hsp27 in four colorectal cancer cell lines were determined by real-time
PCR analysis of Hsp mRNAs before and 24 h after irinotecan treatment. Relative expression values in real-time PCR were obtained by the equation:
relative expression Hsp27 (y = 2(Ct(y)Ct(GAPDH))). (C) Analysis of Hsp27 promoter activity in KM12C and Colo320 cells. Hsp27 promoter
luciferase-reporter construct was transiently transfected into cells. After irinotecan treatment for 24 h, luciferase activity was assayed and luciferase
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the means ± S.D. from three separate experiments.
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resistance. Cell lines showing intermediate irinotecan resis-
tance (such as KM1214 and KM20) revealed intermediate
expression level of Hsp27 compared to Colo320 and KM12C
cell lines (Fig. 2C), suggesting an association of Hsp27 expres-
sion with the irinotecan resistance of colorectal cancer cell
lines.
To determine whether or not there is diﬀerence in the irino-
tecan-induced expression of Hsp27 between irinotecan-sensi-
tive KM12C cells and irinotecan-resistant Colo320 cells,
KM12C and Colo320 cells were transfected with Hsp27 pro-
moter luciferase-reporter construct. Transient transfection of
Colo320 cells with this construct resulted in luciferase level
4-fold higher than the promoterless control plasmid pGL3ba-
sic. In addition, irinotecan treatment induced the luciferase
level to 10-fold higher than the pGL3basic in Colo320 cells
(Fig. 2D). However, when this construct was transfected into
the KM12C cells, luciferase level was decreased to 0.6-fold of
the pGL3basic control and irinotecan treatment resulted in
further decrease of luciferase level to 0.3-fold of pGL3basic
(Fig. 2D). These results suggest that, while Hsp27 expression
is suppressed and is not induced by irinotecan in irinotecan-
sensitive KM12C cells, Hsp27 is expressed under normal con-
dition and its expression is further increased by irinotecan in
irinotecan-resistant Colo320 cells.3.4. Overexpression induced the resistance of colorectal cancer
cells to irinotecan
Although the results described above demonstrated that ele-
vated levels of Hsp27 were associated with irinotecan resis-
tance, they did not address whether or not Hsp27 was
directly involved in irinotecan resistance in human colorectal
cancer cells. Therefore, we sought to determine if an overex-
pression of Hsp27 could induce irinotecan resistance in irino-
tecan sensitive colorectal cancer cells, KM12C cells. To test
this possibility, Hsp27 expression vector (pcDNA3.1-Hsp27)
was transfected into KM12C cells to establish stably transfec-
ted cells, KM12C/Hsp27. KM12C/pcDNA cells that were sta-
bly transfected with empty vector were used as controls.
The overexpression of Hsp27 in the KM12C/Hsp27 cells was
conﬁrmed by RT-PCR (Fig. 3A) and Western blotting
(Fig. 3B). The Hsp27 protein level of KM12C/Hsp27 cells
was increased by more than 2-fold compared to KM12C cells
(Fig. 3B). As shown in Fig. 3C, while the irinotecan-induced
apoptosis of KM12C/pcDNA cells was similar to that of
KM12C cells, the KM12C/Hsp27 cells showed a decreased iri-
notecan-induced apoptosis to 46% of KM12C cells.
To test whether or not the down-regulation of Hsp27 aﬀects
irinotecan resistance in Colo320 cells, we used an antisense
ODN. Treatment of the Colo320 cells with antisense ODN
against Hsp27 signiﬁcantly reduced the Hsp27 expression level
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Fig. 4. Eﬀects of down-regulation of Hsp27 on the irinotecan-induced
apoptosis in irinotecan-resistant colorectal cancer cell line. Irinotecan-
resistant cell, Colo320, was transfected with 200 nM of Hsp27
antisense or scrambled ODNs and then 2 days after the transfection,
cells were treated with 50 lM irinotecan for 24 h. The expression of
Hsp27 was determined by RT-PCR (A) and Western blotting (B)
before the irinotecan treatment and the irinotecan-induced apoptosis
was determined by TUNEL staining at 24 h after irinotecan treatment
(C).
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cells was reduced to less than 20% of untreated control
(Fig. 4A and B). Down-regulation of the Hsp27 by treatment
with antisense ODN increased the irinotecan-induced apopto-
sis by about 10-fold compared to Colo320 cells (Fig. 4C). As
shown in Fig. 4C, the irinotecan-induced apoptosis of scram-
bled ODN-treated Colo320 cells slightly increased compared
to that of Colo320 cells, which may be explained by the
non-speciﬁc eﬀects of ODN. These results indicate that the
expression of Hsp27 is directly associated with the irinotecan
resistance of human colorectal cancer cell lines.
3.5. Hsp27 expression reduced the caspase-3 activity
There was a signiﬁcant diﬀerence in caspase-3 activity be-
tween irinotecan-sensitive KM12C and irinotecan-resistant
Colo320 cells. While caspase-3 activity was hardly detected
in irinotecan-treated Colo320 cells, irinotecan treatment in-
duced a 2.4-fold increase in caspase-3 activity in KM12C cells
(Fig. 5A). Treatment of caspase-3 inhibitor, Ac-DEVD-CHO,
suppressed the irinotecan-induced apoptosis of irinotecan-sen-
sitive KM12C cells (Fig. 4B), which suggests that the caspase-3
activity is required for the irinotecan-induced apoptosis of
KM12C cells. To determine whether or not Hsp27 expression
is associated with caspase-3 activity, we analyzed the caspase-3activities among KM12C/Hsp27 cells and antisense ODN-trea-
ted Colo320 cells after irinotecan treatment. While caspase-3
activity of KM12C/Hsp27 cells was reduced to 61% of
KM12C cells, that of antisense ODN-treated Colo320 cells
was increased by 1.6-fold compared to that of untreated
Colo320 cells (Fig. 5A). Overall, these results showed that
Hsp27 expression decreased caspase-3 activity, which coin-
cided with a decreased irinotecan-induced apoptosis.
3.6. Hsp27 expression is up-regulated in irinotecan-resistant
primary tumors
To determine whether or not the relationship between Hsp27
expression and irinotecan resistance detected in cell lines are
clinically relevant, we examined Hsp27 expression level in the
surgically resected primary colorectal tumors from 20 patients
using immunohistochemistry (Fig. 6). Among the 20 samples
used in this study, 6 were from patients classiﬁed as clinical
responders and 16 from non-responders to irinotecan treat-
ment and we compared the Hsp27 expression level among
responders and non-responders. Although both responders
and non-responders expressed Hsp27, we found statistically
signiﬁcant diﬀerences in Hsp27 expression level between
responders and non-responders. The Hsp27 expression level
in non-responders (mean staining score, 6.28; proportion of
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Fig. 5. Eﬀects of Hsp27 expression on caspase-3 activity induced by
irinotecan treatment. (A) Suppression of caspase-3 activity by Hsp27
expression. Cell lysates were prepared at 24 h after from parental
Colo320 and KM12C cells, antisense ODN-treated or scrambled
ODN-treated Colo320 cells and KM12C derivatives stably transfected
with pcDNA3.1-Hsp27, KM12C/Hsp27, or empty vector pcDNA3.1,
KM12C/pcDNA. (B) Requirement of caspase-3 activity in irinotecan-
induced apoptosis of colorectal cancer cells. Irinotecan-sensitive
KM12C cells were treated with 50 lM irinotecan in the absence or
presence of Ac-DEVD-CHO (3 lM and 10 lM). Ac-DEVD-CHO was
added 1 h prior to irinotecan treatment. Irinotecan-induced apoptosis
was determined by TUNEL staining at 24 h after irinotecan treatment.
Caspase-3 activity was measured in cell lysates at 24 h after irinotecan
treatment as described under Section 2. The caspase-3 activity of
parental Colo320 cells was deﬁned as 1.
1654 D.H. Choi et al. / FEBS Letters 581 (2007) 1649–1656high staining score, 64.2%) was signiﬁcantly greater (P for t-
test = 0.045) compared with responders (mean staining score,
3.16; proportion of high staining score, 33.3%). These resultsFig. 6. Immunohistochemical expression of Hsp27 in surgically resected tu
responder (A) showed weaker immunohistochemical reactivity to Hsp27 (stai
(B) (staining score 12).suggest that there is a correlation between the expression of
Hsp27 and the clinical response of colorectal cancer patients
to the irinotecan treatment.4. Discussion
In this study, we have demonstrated a strong positive corre-
lation between cellular Hsp27 level and irinotecan resistance in
human colorectal cancer cells. This suggests that Hsp27
expression is one of major determinants of irinotecan resis-
tance in human colorectal cancer cells. This conclusion was
established by our results showing that the expression level
of Hsp27 was higher in irinotecan-resistant colorectal cancer
cells than in irinotecan-sensitive colorectal cancer cells. In
addition, an overexpression of Hsp27 reverted irinotecan-
sensitive cells to irinotecan-resistant cells and, vice versa, a
suppression of Hsp27 using antisense ODNs reverted irino-
tecan-resistant cells to irinotecan-sensitive cells. There was a
clinical correlation between the expression level of Hsp27
and the irinotecan resistance of colorectal cancer patients. This
suggests that an expression of Hsp27 leads to irinotecan
resistance in human colorectal cancer cells.
In recent years, evidence has accumulated to show that
Hsp27 can inhibit apoptosis [17,23,24]. Since apoptosis induc-
tion is an important mechanism in the irinotecan-induced kill-
ing of tumors [2,3,25], the inhibition of apoptosis by increased
level of Hsp27 may render tumors more resistant to irinotecan.
Our study provides evidence that shows a direct correlation be-
tween Hsp27 expression and irinotecan resistance. These ﬁnd-
ings are consistent with various other studies that link Hsp27
and chemoresistance in diﬀerent cell types. For example,
higher than normal level of Hsp27 expression is commonly
detected in breast [26,27], prostate [28], gastric [29], ovarian
[30], and oral squamous carcinoma cancers [31], as well as in
Hodgkin’s Disease [32]. In addition, several reports have
demonstrated the role of Hsp27 in cisplatin-resistant human
ovarian cancer cells [20,33], doxorubicin-resistant colorectal
cancer cells [9] and Dex-resistant multiple myeloma cells
[34]. Together, all these suggest a role of Hsp27 in mediating
irinotecan resistance in colorectal cancer cells.
Hsp27 level is generally low within unstressed cells and
increases during the stress response [35]. However, the mecha-
nisms that regulate Hsp27 mRNA and protein levels havemors from colorectal cancer patients. Colorectal tumor tissues from
ning score 1), compared to colorectal tumor tissues from non-responder
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conditions, expression level of Hsp27 was low both in
irinotecan-resistant and irinotecan-sensitive cells. However,
after irinotecan treatment, an upregulation of Hsp27 occurred
only in irinotecan-resistant cells. Thus, a diﬀerence in the
irinotecan-induced induction of Hsp27 seemed to be one factor
for the irinotecan resistance of colorectal cancer cells, suggest-
ing that blocking the irinotecan-induced induction of Hsp27
may enhance the therapeutic eﬃciency of irinotecan.
The clinical relevance of our cell line studies was derived
from an examination of Hsp27 expression in resected speci-
mens before irinotecan treatment. High expression level of
Hsp27 in resected specimens before irinotecan treatment corre-
lated with the clinical response of the cancer patients. How-
ever, there were several cases in which, in spite of low levels
of Hsp27 expression, the clinical response of colorectal cancer
patients against irinotecan treatment was negative. Based on
our cell line studies, it is possible that Hsp27 expression was
upregulated after irinotecan treatment in the tumor tissues of
these colorectal cancer patients. It is also possible that drug-
resistant genes other than Hsp27 [5] played a critical role in
the induction of irinotecan resistance. We need to conﬁrm
which one is true.
How does Hsp27 mediate irinotecan resistance in colorectal
cancer cells? Our study provides evidence that caspase-3 activ-
ity is necessary for the irinotecan-induced apoptosis of colorec-
tal cancer cells: (a) irinotecan treatment increased caspase-3
activity in irinotecan-sensitive colorectal cancer cells and (b)
treatment of caspase-3 inhibitor suppressed the irinotecan-in-
duced apoptosis. These results are consistent with other studies
reporting the activation of caspase-3 after a treatment of topo-
isomerase I inhibitor in leukemia cells [36] and hepatoma cells
[37]. Our study also showed that there was an inverse correla-
tion between the expression levels of Hsp27 and caspase-3
activity. This suggests the possibility that Hsp27 decreases cas-
pase-3 activity, which then leads to the irinotecan resistance of
human colorectal cancer cells. Recently, evidences have accu-
mulated to show that Hsp27 can inhibit apoptosis through a
direct inhibition of caspase activation [17,21]. It has been
shown that Hsp27 can inhibit caspase-3 activity by interacting
with the pro-caspase-3 molecule [38,39]. In addition, multiple
studies have shown that Hsp27 can inhibit caspase activity
by preventing a release of cytochrome c [40,41] and Smac
[34] from mitochondria. Recent evidence has also demon-
strated that a signiﬁcant pool of Hsp27 is located in the mito-
chondria and that it may protect against apoptotic stimuli in a
manner similar to Bcl-2 by blocking the release of cytochrome
c [23]. In our study, we did not determine the details about the
mechanisms by which Hsp27 modulates caspase-3 activity in
irinotecan-treated colorectal cancer cells. Nevertheless, our
data demonstrate that Hsp27 modulates caspase-3 activity in
colorectal cancer cells and enables colorectal cancer cells to
evade the cytotoxic eﬀects of irinotecan.
In this study, we have shown for the ﬁrst time that increased
level of Hsp27 rendered colorectal cancer cells more resistant
to irinotecan and that high expression level of Hsp27 in a re-
sected specimen before irinotecan treatment correlated with
the clinical response of the cancer patients. Our results provide
important information to understand the molecular mecha-
nisms that lead to irinotecan resistance and suggests a poten-
tial therapeutic approach for irinotecan-resistant colorectal
cancer.Acknowledgements: This study was supported by grants from the Ul-
san University Hospital and the University of Ulsan. Won Hyuk Lee
was partly supported by the BK21 Program of the Korea Research
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